Just in Cancer Cell 👉Validation of the molecular clusters of the IMmotion151 trial in the JAVELIN Renal 101 dataset #kidneycancer : Excellent commentary highlighting these biomarkers by our fellow Chadi Hage Chehade 👇tinyurl.com/48px5rw8 GU Cancer Research Program @HuntsmanCancer OncoAlert UroToday.com KidneyCAN

This is my favorite coagulation cascade schematic courtesy of Dr. Carerra at UCSD. I am going to get this tattooed on my chest.

⚡️ Cytoreductive nephrectomy in the era of immune checkpoint inhibitors: a U.S. FDA pooled analysis

#KidneyCancer #Immunotherapy

buff.ly/4cygdWQ

⚡️🔥🚨EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer—2024 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative Intent:

⭐️⭐️⭐️ Main Points⭐️⭐️⭐️
✅Initiate screening for prostate cancer (PCa) at 50 years of age, adjusting based on individual life…

💫🌟First-line combination treatment with PARP and androgen receptor–signaling inhibitors in HRR-deficient mCRPC: Applying clinical study findings to clinical practice in the United States🌟💫
Rana McKay Alicia Morgans, MD, MPH
Neeraj Agarwal, MD, FASCO OncoAlert
cancertreatmentreviews.com/article/S0305-…
📢 Key…

This is the #Algorithm we have used during our discussion w/ Aparna Raj Parikh on #ColonCancer
- Clinical Trials should ALWAYS be on our radar!

#OncTwitter #MedTwtitter #gism #MedEd CancerNetwork® #OncEd #crcsm

Lymphoma Classification

Any suggestions/critiques?

Aaron Goodman - “Papa Heme” 𝗡𝗶𝗵𝗮𝗿 𝗗𝗲𝘀𝗮𝗶 MD, DM David Russler-Germain, MD/PhD Eddie Cliff Charles Milrod, MD

📑💊
Differences of CDK4/6 inhibitors
JNCI

✅Preclinical

✔️Affinity to different CDKs
✔️Different effects on senescence and apoptosis
✔️These differences may affect efficacy, side effects and resistance

✅Clinical

➡️Metastatic
✔️Only ribociclib plus letrozole…

💫📢 Highlights from the ARASENS trial on metastatic hormone sensitive prostate cancer💫

🔹 Darolutamide + ADT + docetaxel increases overall survival (OS) in high-volume, high-risk, and low-risk patients.
🔹 High-volume: OS hazard ratio (HR) 0.69, 95% CI (0.57-0.82)
🔹…

This is the #algorithm we have used during our discussion for #HR positive #breastcancer w/ VIRGINIA KAKLAMANI

#bcsm #onctwitter #meded #OncEd #MedTwitter #Oncology CancerNetwork®

KEYNOTE-522 outcomes by RCB out on Annals of Oncology. Largest benefit from pembro was observed in the RCB-2 group. Striking difference in 3-year EFS between RCB-1 (≃84%) and RCB-3 (≃30%): not all residual disease is created equal! annalsofoncology.org/article/S0923-…

Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24 . Has anything changed for you based on these data?

A historic day for #kidneycancer & the field of #oncology as a whole at ASCO #GU24 . Toni Choueiri, MD Dana-Farber & colleagues present the 1st randomized phase 3 study to show a survival advantage w adjuvant PD1 inhibition, reinforcing this approach as SOC. Proud of his tireless…

We love such curves . Huge PFS benifit of Nivo plus IPi in MSI high CRC . Checkmate 8HW .

But take a pause ask these 2
Questions
1 -
2 IO drugs are needed or one is enough? There are
2 deaths in trial arm .

And
2 -
Cross over was not mandatory. Only 45 pts in chemo arm…

Countdown to 2024: #JITCTop10 - Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology bit.ly/3zFQgT3 Jarushka Naidoo Dr. Julie Brahmer Elad Sharon Laura Cappelli

'Luck is what happens when preparation meets opportunity'. Seneca, 1st century CE

Do you know the Mayo classification for IVC thrombus in RCC?

We used to use a 2 cm cutoff above the renal vein as the differentiator between level 1 and 2.

Did you know an updated classification was published in 2020? We should now use the caudate lobe as differentiator.

How far have we come in over 200 years of work in prostate cancer? See the timeline below from Charlie Dai for an amazing distillation Journal of Clinical Oncology. Now we are here #PCFRetreat23 to take the next steps! PCF Science ascopubs.org/doi/full/10.12…

Nivolumab consigue el 'doctorado en SG' en cáncer de vejiga.

Ya tenemos 3 I/O doctorados: Pembrolizumab, Avelumab y Nivolumab. Una gran oportunidad que deberemos aprender a gestionar.

No es justo que este esfuerzo y esta curva se queden sin aplauso. Ahí va el mío: 👏👏👏👏.

Enfortumab vedotin & Pembrolizumab improving PFS & OS by 55% & 53% respectively compared to platinum based chemo in 1st line UC (+avelumab in 30%). Chemo has not been beaten before (despite multiple efforts). RR and CR of 68% & 29% is hard to beat. DOR not reached (1/3) #ESMO2023